At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 58 enrolled
Drug / intervention
Insulin Glargine +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Relative Bioavailability of LY2963016 to LANTUS® After Single-Dose Subcutaneous Administration in Healthy Chinese Subjects
In Brief
A Phase 1 clinical trial evaluating Insulin Glargine and Lantus for Healthy. Completed, enrolled 58 participants across 1 site.
Detailed Summary
The purpose of this study is to compare a study drug known as Insulin glargine with Lantus in healthy Chinese participants. Blood samples will be taken to compare how the body handles the drugs and how they affect blood sugar levels. Side effects and tolerability will be documented. The study will last at least 18 days, not including screening. Screening is required within 4 weeks prior to the start of the study.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy
CountriesChina
Collaborators--
Timeline
Phase 1CompletedFinished
20192020202120222023202420252026
First PostedJun 2018
Enrollment StartSep 2018
Primary CompletionNov 2019
TodayJul 2026
First PostedJun 13, 2018
Enrollment StartSep 26, 2018
Primary CompletionNov 4, 2019
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 8.1 years ago
Interventions
Insulin Glarginedrug
Administered SC
Lantusdrug
Administered SC